Alice Assinger: Thrilled to Be Selected for The New doc.funds Programme!
Alice Assinger, Professor at the Medical University of Vienna, reposted from Austrian Science Fund FWF on LinkedIn:
”Thrilled to be selected for the new doc.funds programme!
Our project will focus on uncovering the network of vascular inflammation and thrombosis – an area I’m incredibly passionate about.
A heartfelt thank-you to the amazing NET-IT team – Cihan Ay, Christoph Binder, Christine Brostjan, Philipp Hohensinner, Bernd Jilma, Sylvia Knapp, Robert Kralovics, Antonia Mueller, Dimitrios Tsiantoulas – your dedication made this possible.
I’m excited to begin this journey and work with our future PhD students on advancing this important field.”
Quoting Austrian Science Fund FWF‘s post:
”Seven research teams are receiving support as part of the doc.funds funding program: With around €16.5 million, the Austrian Science Fund FWF is providing a strong impetus for 65 new doctoral positions and for the next generation of excellent research at universities in Austria.
The new doctoral positions will be created at the University of Graz, Graz University of Technology, Medical University of Graz, Medical University of Vienna, and WU (Vienna University of Economics and Business).
All new doc.funds in detail”
Stay updated with Hemostasis Today.
-
Aug 11, 2026, 07:50When Access to Care Changes Everything – WFH
-
Aug 11, 2026, 07:41Kevin Land: How Cellular Therapy Is Changing Transfusion Medicine
-
Aug 11, 2026, 07:35Kuldeep Singh Bhadauria: Building the Future of Hemophilia Care in India
-
Aug 11, 2026, 07:28Archil Jaliashvili: When Every Minute Matters Time Becomes a Therapy
-
Aug 11, 2026, 07:05Mavis Agnes Kisakye: Building Sustainable Transition Pathways in Hemophilia Care
-
Aug 11, 2026, 06:48Rishdha Roshad: What Happens to the Brain During Cardiopulmonary Bypass?
-
Aug 11, 2026, 05:53Isaac Okello: Strengthening Sickle Cell Advocacy in Uganda
-
Aug 11, 2026, 05:38Rami Unterman: A Simple New Biomarker for Fibrotic ILDs
-
Aug 11, 2026, 04:10Haroun Gajraj: CLaCS vs Sclerotherapy – What Does the Evidence Show